TSPYL5 is involved in cell growth and the resistance to radiation in A549 cells via the regulation of p21WAF1/Cip1 and PTEN/AKT pathway

Biochemical and Biophysical Research Communications

Volumn 392, Issue 3, 2010, Pages 448-453

  Kim, Eun Jin ^a   Lee, So Yong ^a   Kim, Tae Rim ^a   Choi, Soo Im ^a   Cho, Eun Wie ^b   Kim, Kug Chan ^a   Kim, In Gyu ^a  

^a Korea Atomic Energy Research Institute   (South Korea)

^b Korea Research Institute of Bioscience and Biotechnology (KRIBB)   (South Korea)

Author keywords

Radiation; AKT; PTEN; TSPYL5

Indexed keywords

CISPLATIN; CYCLIN DEPENDENT KINASE INHIBITOR 1; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE B; TESTIS SPECIFIC Y LIKE PROTEIN 5; TUMOR PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CANCER RESISTANCE; CARCINOMA CELL; CHEMOSENSITIZATION; CONTROLLED STUDY; DNA METHYLATION; ENZYME ACTIVATION; ENZYME INACTIVATION; ENZYME INHIBITION; ENZYME REGULATION; GAMMA RADIATION; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENE INDUCTION; GENE OVEREXPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; PRIORITY JOURNAL; PROTEIN INDUCTION; RADIOSENSITIVITY; RADIOSENSITIZATION; RNA INTERFERENCE; SIGNAL TRANSDUCTION; TUMOR GROWTH; TUMOR PROMOTION; UPREGULATION;

APOPTOSIS; BASE SEQUENCE; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; CELL PROLIFERATION; CPG ISLANDS; CYCLIN-DEPENDENT KINASE INHIBITOR P21; DNA METHYLATION; GAMMA RAYS; HUMANS; LUNG NEOPLASMS; MOLECULAR SEQUENCE DATA; NUCLEAR PROTEINS; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; PTEN PHOSPHOHYDROLASE; RADIATION TOLERANCE;

EID: 76349100736     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2010.01.045     Document Type: Article

References (32)

1. Albert M., and Peters A.H. Genetic and epigenetic control of early mouse development. Curr. Opin. Genet. Dev. 19 (2009) 113-121
2. Jones P.A., and Baylin S.B. The epigenomixs of cancer. Cell 128 (2007) 638-692
3. Pogribny I.P., and Beland F.A. DNA hypomethylation in the origin and pathogenesis of human diseases. Cell Mol. Life Sci. 66 (2009) 2249-2261
4. Hirst M., and Marra M.A. Epigenetics and human disease. Int. J. Biochem. Cell Biol. 41 (2009) 136-146
5. Oka D., Yamashita S., Tomioka T., Nakanishi Y., Kato H., Kaminishi M., and Ushijima T. The presence of aberrant DNA methylation in noncancerous esophageal mucosae in association with smoking history: a target for risk diagnosis and prevention of esophageal cancers. Cancer 115 (2009) 3412-3426
6. Koga Y., Pelizzola M., Cheng E., Krauthammer M., Sznol M., Ariyan S., Narayan D., Molinaro A.M., Halaban R., and Weissman S.M. Genome-wide screen of promoter methylation identifies novel markers in melanoma. Genome Res. 19 (2009) 1462-1470
7. Marsit C.J., Christensen B.C., Houseman E.A., Karagas M.R., Wrensch M.R., Yeh R.F., Nelson H.H., Wiemels J.L., Zheng S., Posner M.R., McClean M.D., Wiencke J.K., and Kelsey K.T. Epigenetic profiling reveals etiologically distinct patterns of DNA methylation in head and neck squamous cell carcinoma. Carcinogenesis 30 (2009) 416-422
8. Kim T.Y., Zhong S., Fields C.R., Kim J.H., and Robertson K.D. Epigenomic profiling reveals novel and frequent targets of aberrant DNA methylation-mediated silencing in malignant glioma. Cancer Res. 66 (2006) 7490-7501
9. Jung Y., Park J., Bang Y.J., and Kim T.Y. Gene silencing of TSPYL5 mediated by aberrant promoter methylation in gastric cancers. Lab. Invest. 88 (2008) 153-160
10. Vachani A., Nebozhyn M., Singhal S., Alila L., Wakeam E., Muschel R., Powell C.A., Gaffney P., Singh B., Brose M.S., Litzky L.A., Kucharczuk J., Kaiser L.R., Marron J.S., Showe M.K., Albelda S.M., and Showe L.C. A 10-gene classifier for distinguishing head and neck squamous cell carcinoma and lung squamous cell carcinoma. Clin. Cancer Res. 13 (2007) 2905-2915
11. Das A.K., Sato M., and Story M.D. Non-small-cell lung cancers with kinase domain mutations in the epidermal growth factor receptor are sensitive to ionizing radiation. Cancer Res. 66 (2006) 9601-9608
12. Kraus-Berthier L., Jan M., Guilbaud N., Naze M., Pierré A., and Atassi G. Histology and sensitivity to anticancer drugs of two human non-small cell lung carcinomas implanted in the pleural cavity of nude mice. Clin. Caner Res. 6 (2000) 297-304
13. Tost J., Gut I.G., and NA D. DNA methylation analysis by pyrosequencing. Nat. Protoc. 2 (2007) 2265-2275
14. Klein S., and Levitzki K. Targeting the EGFR and PKB pathway in cancer. Curr. Opin. Cell Biol. 21 (2009) 185-193
15. LoPiccolo J., Granville C.A., Gills J.J., and Dennis P.A. Targeting Akt in cancer therapy. Anticancer Drugs 18 (2007) 861-874
16. Rayet B., and Gelinas C. Abberant Rel/NFkB genes and activity in human cancer. Oncogene 18 (1999) 6938-6947
17. Rowland B.D. D.S. Peeper. KLF4, p21 and context-dependent opposing forces in cancer. Nat. Rev. Cancer 6 (2006) 11-23
18. Hemstrom T.H., Sandstrom M., and Zhivotovsky B. Inhibitors of the PI3-kinase/Akt pathway induce mitotic catastrophe in non-small cell lung cancer cells. Int. J. Cancer 119 (2006) 1028-1038
19. Baumann M., Krause M., and Dikomey E. EGFR-targeted anti-cancer drugs in radiotherapy: preclinical evaluation of mechanisms. Radiother. Oncol. 83 (2007) 238-248
20. Krause M., Zips D., Thames H.D., Kummermehr J., and Baumann M. Preclinical evaluation of molecular-targeted anticancer agents for radiotherapy. Radiother. Oncol. 80 (2006) 112-122
21. Vogel T., Dittrich O., Mehraein Y., Dechend F., Schnieders F., and Schmidtke J. Murine and human TSPYL genes: novel members of the TSPY-SET-NAP1L1 family. Cytogenet. Cell Genet. 81 (1998) 265-270
22. Grasberger H., and Bell G.I. Subcellular recruitment by TSG118 and TSPYL implicates a role for zink finger protein 106 in a novel developmental pathway. Int. J. Biochem. Cell Biol. 37 (2005) 1421-1437
23. Chapman E.J., Kelly G., and Knowles M.A. Genes involved in differentiation, stem cell renewal, and tumorigenesis are modulated in telomerase-immortalized human urothelial cells. Mol. Cancer Res. 6 (2008) 1154-1168
24. Albert J.M., Kim K.W., Cao C., and Lu B. Targeting the Akt/mammalian target of rapamycin pathway for radiosensitization of breast cancer. Mol. Cancer Ther. 5 (2006) 1183-1189
25. Nakamura J.L., Karlsson A., and Arvold N.D. PKB/Akt mediates radiosensitization by the signaling inhibitor LY294002 in human malignant gliomas. J. Neurooncol. 71 (2005) 215-222
26. Lee C.M., Fuhrman C.B., and Planelles V. Phosphatidylinositol 3-kinase inhibition by LY294002 radiosensitizes human cervical cancer cell lines. Clin. Cancer Res. 12 (2006) 250-256
27. Li B., Desai S.A., MacCorkle-Chosnek R.A., Fan L., and Spencer D.M. A novel conditional Akt survival 'switch' reversibly protects cells from apoptosis. Gene Ther. 9 (2002) 233-244
28. Lee S.M., Lee C.T., Kim Y.W., Han S.K., Shim Y.S., and Yoo C.G. Hypoxia confers protection against apoptosis via PI3K/Akt and ERK pathways in lung cancer cells. Cancer Lett. 242 (2006) 231-238
29. Liang G., Bansal G., Xie Z., and Druey K.M. RGS16 inhibits breast cancer cell growth by mitigating phosphatidylinositol 3-kinase signaling. J. Biol. Chem. 284 (2009) 21719-21727
30. Woo K.J., Jeong Y.J., Park J.W., and Kwon T.K. Chrysin-induced apoptosis is mediated through caspase activation and Akt inactivation in U937 leukemia cells. Biochem. Biophys. Res. Commun. 325 (2004) 1215-1222
31. Uddin S., Hussain A., Al-Hussein K., Platanias L.C., and Bhatia K.G. Inhibition of phosphatidylinositol 3′-kinase induces preferentially killing of PTEN-null T leukemias through AKT pathway. Biochem. Biophys. Res. Commun. 320 (2004) 932-938
32. Lee S.Y., Hur G.Y., Jung K.H., Jung H.C., Lee S.Y., Kim J.H., Shin C., Shim J.J., In K.H., Kang K.H., and Yoo S.H. PPAR-gamma agonist increase gefitinib's antitumor activity through PTEN expression. Lung Cancer 51 (2006) 297-301